Bicycle Therapeutics
About Bicycle Therapeutics
Bicycle Therapeutics is a Cambridge-based biotech pioneering bicyclic peptide (Bicycle) therapeutics for oncology and other diseases.
Milestones
Milestones as listed on bicycletherapeutics.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on bicycletherapeutics.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on bicycletherapeutics.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Bicycle Drug Conjugates
Bicycle molecule, cleavable linker and small-molecule payload aimed at tumour antigens.
Source: bicycletherapeutics.comBicycle Radioligands
Bicycle molecule with linker-chelator carrying a therapeutic or imaging radioisotope.
Source: bicycletherapeutics.comnuzefatide pevedotin (BT5528)
EphA2-targeting drug conjugate in a Phase II trial in metastatic pancreatic cancer.
Source: bicycletherapeutics.comzelenectide pevedotin (BT8009)
Nectin-4-targeting drug conjugate studied in metastatic urothelial cancer; site says the program has been deprioritised.
Source: bicycletherapeutics.comBT1702
MT1-MMP-targeting radioligand using lead-212; first company-sponsored trial planned for 2027.
Source: bicycletherapeutics.comFinancials & Irish Entities
From the annual reports Bicycle Therapeutics plc files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $72.6m | $240m | 331.0% | −$219m | 10-K 2026 |
| Dec 2024 | $35.3m | $173m | 490.3% | −$169m | 10-K 2026 |
| Dec 2023 | $27.0m | $156m | 580.1% | −$181m | 10-K 2026 |
| Dec 2022 | $14.5m | $81.6m | 564.3% | −$113m | 10-K 2025 |
| Dec 2021 | $11.7m | $44.9m | 383.7% | −$66.8m | 10-K 2024 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.